PT-141: A Melanocortin Peptide Studied for Sexual Desire and Arousal.

What PT-141 Is — and Isn't.

PT-141 (bremelanotide) is a cyclic heptapeptide. It is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), and it acts as an agonist at melanocortin receptors in the central nervous system — primarily MC4R, and to a lesser extent MC3R. These receptors sit in brain pathways that modulate sexual desire and arousal.

The mechanism distinction matters. PT-141 is not a vascular medication. It does not work the way Viagra (sildenafil) or Cialis (tadalafil) work. PDE5 inhibitors act on peripheral vascular smooth muscle to support erection. PT-141 acts centrally on desire and arousal. For some patients, the two interventions address different problems — and the right intervention depends on what the actual problem is. We evaluate that first.

Why We Evaluate Hormones First.

Sexual desire and arousal are multifactorial. Patients presenting with low libido, reduced arousal, or changes in sexual function commonly have one or more of the following contributing factors:

• Hormone decline — testosterone (in both men and women), estradiol, thyroid, DHEA-S. The leading driver in the demographic we see.
• Medication side effects — SSRIs and SNRIs are common; some antihypertensives, finasteride/5-alpha-reductase inhibitors, hormonal contraception, and certain other agents are also implicated.
• Sleep, stress, cortisol patterns — chronic poor sleep and elevated stress suppress the entire hypothalamic-pituitary-gonadal axis.
• Vascular and cardiovascular health — particularly in men, where erectile function depends on vascular integrity.
• Mood and relationship factors — not addressable through peptide therapy.

PT-141 acts on one specific pathway. If hormones are suppressed, if a medication is contributing, if vascular health is the actual issue, peptide therapy alone is unlikely to resolve the concern. Our standard sequence: comprehensive evaluation through the CLARITY methodology, address modifiable drivers, then consider PT-141 if the concern persists and the underlying picture supports it.

Candidacy — Who PT-141 Is For.

Patients with persistent low desire or arousal — in the context of treated or normal hormone levels — for whom the clinical picture supports the melanocortin pathway as a relevant intervention. Specifically:

• Premenopausal women with HSDD (the FDA-approved indication).
• Patients (men or post-menopausal women) with persistent desire/arousal concerns despite hormone optimization and medication review.
• Patients for whom PDE5 inhibitors have not addressed the underlying concern, suggesting the mechanism mismatch (vascular vs. central) is the issue.

Candidacy is not assessed by symptom alone — it is assessed by symptom plus baseline hormonal data plus cardiovascular safety screening. We do not prescribe PT-141 as a first-line intervention. It is layered after the hormone and medication review.

Safety Screening and Monitoring.

Cardiovascular evaluation

PT-141 produces a small, transient elevation in blood pressure (per Vyleesi labeling, approximately 6 mmHg average systolic increase, peaking within hours). Patients with uncontrolled hypertension or established cardiovascular disease require thorough evaluation before any prescription. Patients on antihypertensive medications require coordination.

Blood pressure monitoring

Baseline BP at evaluation; periodic re-measurement on therapy. Patients with home BP monitors are encouraged to track responses to early doses.

Clinical response

Response tracking across multiple administrations — not all patients respond. Side-effect tolerability (especially nausea) is part of the candidacy continuation decision. We do not continue prescribing if a patient is not benefiting.

How It Pairs With Other Interventions.

PT-141 is rarely used in isolation. Patients we see typically benefit from a combined approach:

• Hormone optimization — the most common upstream intervention. Restoring testosterone, estradiol, and thyroid function often resolves the concern without further pharmacology.
• Medication review — coordinating with prescribers on SSRIs, antihypertensives, finasteride, and other agents that may be contributing.
• Comprehensive sexual wellness evaluation — which addresses both clinical and lifestyle factors.
• PDE5 inhibitors for patients where vascular contribution is documented — these are first-line for erectile concerns and prescribed by primary care or urology.

For patients whose concern is primarily desire and arousal (not vascular performance), and where hormones and other modifiable factors have been addressed, PT-141 can be the right layered addition.